# LEAP-015 (NCT04662710)

> Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

No report yet. It can be ordered.

- Drugs tested: lenvatinib plus pembrolizumab
- Indication: first-line advanced/metastatic gastroesophageal adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04662710
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Advanced/Metastatic Gastroesophageal Adenocarcinoma
- Interventions: Pembrolizumab; Lenvatinib; Oxaliplatin; Capecitabine; Leucovorin (or Levoleucovorin); 5-FU
- Enrollment: 895
- Primary outcome: Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
- Primary outcome: Part 1: Number of Participants With Adverse Events (AEs)
- Primary outcome: Part 1: Number of Participants Who Discontinued Study Treatment Due to an AE
- Primary outcome: Part 2: Overall Survival (OS) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1
- Primary outcome: Part 2: OS in All Participants
- Primary outcome: Part 2: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 CPS ≥1
- Primary outcome: Part 2: PFS Per RECIST 1.1 as Assessed by BICR in All Participants

## Indexed commentary on LEAP-015 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 22
- YouTube: 2
- Podcasts: 2

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=leap-015-nct04662710

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04662710", "email": "<work email>"}; the inbox owner confirms by the emailed link.